In a phase 3 trial of 636 patients with advanced non-squamous NSCLC, first-line serplulimab plus chemotherapy improved median PFS vs chemotherapy alone (11.0 vs 5.6 months; HR 0.55); adding HLX04 gave no further benefit (HR 0.86). Serious related events: 37% vs 24%.
RCTn = 636
Wang et al. First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial